tpst1120,nivolumab,atezolizumab,bevacizumab
medsir,roche,bms,tempest therapeutics
['nivo', 'tpst-1120 ', 'hcc', 'atezo', 'nivolumab', 'medsir']
 honored to present these phase 1 data at #asco22. tpst-1120 plus nivolumab induced responses in pts with prior anti-pd1 progression, further development planned w/ atezo/bev in hcc
Medical oncologist @ Johns Hopkins, focused on translational research for hepatobiliary cancers (HCC, cholangiocarcinoma)